Hypothesis

Somatic cells can achieve germline‑like epigenetic fidelity by transiently suppressing KDM6B while boosting α‑ketoglutarate (α‑KG) levels, thereby unleashing KDM6A‑mediated H3K27me3 erasure and resetting chromatin accessibility without triggering oncogenic transformation.

Rationale

• Germline epigenome stays young because high KDM6A activity constantly removes repressive H3K27me3, whereas somatic aging shifts the balance to high KDM6B / low KDM6A [PMC6280793 [PMC8688854].
• KDM6B knockdown paradoxically upregulates KDM6A, suggesting a feedback loop where KDM6B restrains KDM6A expression or activity [PMC6280793].
• Somatic hypoxia and oncometabolites (e.g., 2‑hydroxyglutarate) inhibit KDM6A via low α‑KG / high 2‑HG, while HIF‑1/mTOR drives KDM6B expression [PMC8688854].
• Bivalent domains may not coexist on the same nucleosome; instead, the germline retains the capacity to rapidly switch between H3K4me3‑active and H3K27me3‑repressive states [PMC2746918]—a dynamic capacity lost in aged soma.

Thus, reproducing the germline’s KDM6A‑dominant, KDM6B‑repressed milieu in somatic tissue should reset the H3K27me3 landscape, restore enhancer‑promoter accessibility, and delay epigenetic aging.

Experimental Design

Model: Inducible, tissue‑specific KDM6B knockdown (shRNA or CRISPRi) in aged (18‑month) mice, combined with dietary α‑KG supplementation (2 % w/w) to ensure co‑factor abundance.

Groups (n = 15 per group):

1. Young control (3 mo, wild‑type).
2. Aged control (18 mo, wild‑type).
3. Aged + KDM6B knockdown only.
4. Aged + α‑KG diet only.
5. Aged + KDM6B knockdown + α‑KG diet (experimental).
6. Aged + scrambled shRNA + α‑KG diet (vector control).

Intervention timeline: 8 weeks of doxycycline‑induced KDM6B knockdown; α‑KG provided throughout.

Readouts (performed at week 0, 4, 8, and 12 post‑start):

• Chromatin: CUT&RUN for H3K27me3 and H3K4me3 at promoters/enhancers; calculate global H3K27me3 loss and focal gains at developmental regulators.
• Transcriptome: RNA‑seq to assess re‑activation of germline‑associated genes (e.g., Dazl, Sycp1) and silencing of senescence‑associated secretory phenotype (SASP) factors.
• Metabolomics: LC‑MS quantification of α‑KG, 2‑HG, succinate in target tissue to confirm co‑factor shift.
• Cellular senescence: β‑galactosidase staining, p16^Ink4a^ and p21^Cip1^ protein levels.
• Functional assays: Grips strength, treadmill endurance, and frailty index.
• Longevity: Survival monitoring up to 30 months.

Expected Outcomes

If the hypothesis is correct, group 5 will show:

• A significant reduction in global H3K27me3 (≈30‑40 % vs aged control) without loss of H3K4me3 at active promoters, mirroring the germline pattern.
• Re‑expression of germline‑protective transcripts and downregulation of SASP, indicating a shift toward a more plastic, less senescent state.
• Improved metabolic profile: ↑α‑KG/↓2‑HG ratio, supporting KDM6A activity.
• Delayed onset of frailty and extended median lifespan (≥15 % increase) relative to aged controls.
• No increase in tumorigenesis, as KDM6A elevation is tumor‑suppressive and KDM6B reduction counteracts its oncogenic drive.

Control groups should display intermediate or null effects, confirming that both KDM6B suppression and α‑KG availability are required for the reset.

Falsifiability

Failure to observe concomitant H3K27me3 loss and functional improvement in group 5, or detection of hyperproliferative lesions, would falsify the hypothesis. Additionally, if KDM6B knockdown alone (group 3) reproduces the full phenotype, the α‑KG component would be deemed unnecessary, prompting mechanistic revision.

Broader Impact

Demonstrating that somatic epigenetics can be reprogrammed by mimicking germline demethylase balance offers a non‑genetic, metabolically grounded strategy to combat age‑related epigenetic drift, with potential translation to intermittent dietary or pharmacological regimens in humans.